Company news, research breakthroughs, and major announcements across industries.

Home/Science

Science

Hibsago (bepirovirsen) Approved in the US for the Treatment of Chronic Hepatitis B (CHB)

H

GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Hibsago (bepirovirsen) for the treatment of chronic hepatitis B (CHB) virus infection in combination with nucleos(t)ide analogue reverse transcriptase inhibitor (NrtI) therapy in adult patients without cirrhosis, receiving NrtI therapy for at least 6 months, who have suppressed HBV deoxyribonucleic acid (DNA), and with hepatitis B virus (HBV) surface antigen (HBsAg)...

  • PublishedOctober 20, 2026 · 7:58 PM
  • LocationPHILADELPHIA
  • IndustryScience
  • LanguageEN

Published by Business Wire. Read the original announcement for the full release.

Read the full announcement →

Latest from leading organizations

Explore recent announcements by organization